AlzeCure Pharma
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sl… Read more
AlzeCure Pharma (ALZCUR) - Total Liabilities
Latest total liabilities as of September 2025: Skr15.93 Million SEK
Based on the latest financial reports, AlzeCure Pharma (ALZCUR) has total liabilities worth Skr15.93 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AlzeCure Pharma - Total Liabilities Trend (2017–2024)
This chart illustrates how AlzeCure Pharma's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AlzeCure Pharma Competitors by Total Liabilities
The table below lists competitors of AlzeCure Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thai Rubber Latex Group Public Company Limited
BK:TRUBB
|
Thailand | ฿4.73 Billion |
|
Asia Precision Public Company Limited
BK:APCS
|
Thailand | ฿1.54 Billion |
|
Healthconn Corp.
TWO:6665
|
Taiwan | NT$622.49 Million |
|
iZafe Group AB Series B
ST:IZAFE-B
|
Sweden | Skr23.71 Million |
|
Rocky Mountain Chocolate Factory
NASDAQ:RMCF
|
USA | $14.72 Million |
|
Wellysun Inc
TW:6988
|
Taiwan | NT$465.80 Million |
|
Radhika Jeweltech Limited
NSE:RADHIKAJWE
|
India | ₹823.02 Million |
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
USA | $5.06 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down AlzeCure Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AlzeCure Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AlzeCure Pharma (2017–2024)
The table below shows the annual total liabilities of AlzeCure Pharma from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr8.25 Million | +0.28% |
| 2023-12-31 | Skr8.23 Million | -20.54% |
| 2022-12-31 | Skr10.35 Million | -18.30% |
| 2021-12-31 | Skr12.67 Million | +79.20% |
| 2020-12-31 | Skr7.07 Million | +48.95% |
| 2019-12-31 | Skr4.75 Million | +2.93% |
| 2018-12-31 | Skr4.61 Million | +11.26% |
| 2017-12-31 | Skr4.15 Million | -- |